Share Price, page-566

Time for our monthly FDA accountability update.

Merck's new COVID anti-viral pill Molnupiravir is set to get approval from the FDA after an advisory panel of experts voted 13 to 10, to approve it.

This is the drug that has an unknown long-term side-effect profile (was rushed through) and one that could be dangerous because it may interfere with our own DNA, due to its mechanism of action.

Results - 30% effective against death and hospital vs placebo. 30%....there is an argument that 30% is better than nothing if there was no alternative. The problem is we do have another alternative to COVID. We have effective vaccines and Pfizers new anti-viral drug that is 89% effective at reducing death and hospitalisation...

On what balls of steel does the FDA stand on to reject Trofenitide? On what basis could it possibly be, because not one person has yet come up with anything. An orphan drug treating a condition in which no other drug has yet demonstrated any efficacy to treat. Extremely high-standards in our trials plus our results that make Molnupiravir look like a joke.

Strap yourselves in boys.